@noxopharm.bsky.social
📤 7
đź“Ą 9
đź“ť 50
Professor Michael Gantier
@gantierlab.bsky.social
from
@hudsonresearch.bsky.social
, Noxopharm’s strategic partner, will be a keynote speaker at a free international webinar on 17 June. More details including specific timings and a registration link can be found here:
sciforum.net/event/Pharma...
loading . . .
https://sciforum.net/event/Pharmaceuticals-9
about 10 hours ago
0
0
0
New data from Noxopharm (ASX:NOX) shows its Sofra™ platform can amplify TLR8 immune response 200-fold, unlocking potent new cancer immunotherapy potential in a $185B market by 2035.
bit.ly/3Pl6Gvy
#biotech
#ImmunoOncology
loading . . .
https://bit.ly/3Pl6Gvy
7 days ago
0
3
0
Noxopharm (ASX:NOX) Sofra™ platform data is to be presented by CSL at top global influenza conference, highlighting its potential to enhance self-amplifying mRNA vaccine delivery.
bit.ly/4dBMk9k
#Biotech
#Immunotherapy
loading . . .
https://bit.ly/4dBMk9k
13 days ago
0
1
0
Noxopharm (ASX:NOX) advances US FDA pre-IND strategy for SOF-SKN™, targeting $3.3B+ autoimmune skin disease market. Engages global CRO Novotech to boost regulatory and commercial potential.
#Biotech
#DrugDevelopment
bit.ly/49dSDyk
loading . . .
https://bit.ly/49dSDyk
27 days ago
0
0
0
New data demonstrates SOF-16, the active ingredient in SOF-SKN, effectively blocks inflammation in blood and joint fluid samples from lupus and rheumatoid arthritis patients. This supports further development of SOF-SKN for autoimmune diseases. Announcement:
www.noxopharm.com/pdf/e6d6d6bf...
loading . . .
https://www.noxopharm.com/pdf/e6d6d6bf-be15-4bdd-82b3-344383090f55/New-data-shows-SOFSKN-active-ingredient-efficacy.pdf?Platform=ListPage
about 1 month ago
0
0
0
Noxopharm has announced positive results from InhaTarget Therapeutics, a company with a unique inhalation-based delivery system that is testing Sofra™ technology platform assets. Read the announcement here:
www.noxopharm.com/pdf/deb770c3...
loading . . .
https://www.noxopharm.com/pdf/deb770c3-2b0a-490b-9de8-5028340de40d/Innovative-collaboration-further-expands-Sofra-platform.pdf?Platform=ListPage
about 1 month ago
0
0
0
Noxopharm’s latest quarterly is now out, with news of an MoU with US company Tezcat Biosciences, signalling a mutual intent to deepen collaboration in the months ahead and building on the success of an ongoing collaboration. Read the quarterly here:
www.noxopharm.com/pdf/2e566eae...
loading . . .
https://www.noxopharm.com/pdf/2e566eae-577e-4b87-be8c-08bcd0df5c27/March-2026-Quarterly-Activities-Report-and-Appendix-4C.pdf?Platform=ListPage
about 1 month ago
0
0
0
Noxopharm has announced promising new data in support of a future human trial for SOF-SKN™, the company’s cutaneous lupus drug candidate, confirming several important characteristics of the drug and representing a positive step in its refinement. Read more here:
www.noxopharm.com/pdf/a094654d...
loading . . .
https://www.noxopharm.com/pdf/a094654d-b864-451e-a88d-57d14eec1d92/Positive-SOFSKN-dosing-data-shows-prolonged-skin-retention.pdf?Platform=ListPage
about 1 month ago
0
0
0
Noxopharm is pleased to announce the appointment of Dr Olivier Laczka as its new Chief Executive Officer with immediate effect. Dr Laczka has been the driving force behind company’s promising Sofra™ platform for the past several years. Read the announcement here:
www.noxopharm.com/pdf/52caff1f...
loading . . .
https://www.noxopharm.com/pdf/52caff1f-1ecd-4d5e-a1c3-096b22f8b201/Noxopharm-appoints-Dr-Olivier-Laczka-as-new-CEO.pdf?Platform=ListPage
about 2 months ago
0
0
0
New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules
signals.cytokinesociety.org/2026/03/14/g...
loading . . .
New Checkpoint in TLR7/8 Sensing Rewrites Innate Immune Rules - Biweekly newsletter of The Cytokine Society
A study from the Gantier lab (Hudson Institute/Monash University), published in Nature Immunology, reveals that naturally occurring 2′-O-methyl-guanosine RNA fragments act as potent antagonists of TLR7 and TLR8, binding a previously unknown site to keep the receptors in an inactive state.
https://signals.cytokinesociety.org/2026/03/14/gantier-lab-tlr7-8-article-nature-immunology/
3 months ago
0
0
0
Noxopharm has received a $2,806,583.03 rebate under the Australian Government’s Research and Development Tax Incentive scheme for expenditure during FY 2025. Read more here:
www.noxopharm.com/pdf/e2e613a6...
loading . . .
https://www.noxopharm.com/pdf/e2e613a6-ef79-40cc-8286-d113baf4c460/RD-rebate-strengthens-cash-position.pdf?Platform=ListPage
3 months ago
0
0
0
Noxopharm (ASX:NOX) has signed a $5 million At-the-Market equity deal with Acuity Capital, securing flexible standby funding through 2031 with full discretion on share issuance and pricing.
www.noxopharm.com/pdf/647ad621...
loading . . .
https://www.noxopharm.com/pdf/647ad621-f7b9-4c37-a074-277b17f95a34/AttheMarket-ATM-agreement-with-Acuity-Capital.pdf?Platform=ListPage
3 months ago
0
1
0
Professor Michael Gantier is the lead author on the paper, which involved several teams of national and international researchers.
add a skeleton here at some point
4 months ago
0
1
0
Noxopharm and
@hudsonresearch.bsky.social
announce a breakthrough scientific paper regarding the Sofra™ platform in top-ranking journal Nature Immunology. Read the full announcement here:
www.noxopharm.com/pdf/e17f82ba...
loading . . .
https://www.noxopharm.com/pdf/e17f82ba-fa5f-466f-8c30-00a3d5039098/Sofra-breakthrough-science-publish-in-major-medical-journal.pdf?Platform=ListPage
4 months ago
0
1
1
Noxopharm’s latest quarterly is now out, covering more external interest in the company’s Sofra platform and the recent successful conclusion of the HERACLES clinical trial. Read more here:
www.noxopharm.com/pdf/35e7336f...
loading . . .
https://www.noxopharm.com/pdf/35e7336f-bade-46e1-a82f-3fea44397d64/December-2025-Quarterly-Activities-Report-and-Appendix-4C.pdf?Platform=ListPage
4 months ago
0
0
0
Noxopharm announces the final cohort of SOF-SKN™ has been completed in the HERACLES trial. The clinical part of the trial has now successfully concluded, with a highly positive safety outcome for all dosing groups. Read more here:
www.noxopharm.com/pdf/70fe930c...
loading . . .
https://www.noxopharm.com/pdf/70fe930c-eee2-43c7-896c-c0bbb845ce13/HERACLES-clinical-trial-successfully-completed.pdf?Platform=ListPage
4 months ago
0
0
0
To start the year, Noxopharm CEO Dr Gisela Mautner is featured in a great article from BioSpectrum Asia on why mRNA technology represents a huge opportunity for the APAC region.
www.biospectrumasia.com/analysis/29/...
loading . . .
The Future of mRNA Is Being Built in APAC
The Future of mRNA Is Being Built in APAC
https://www.biospectrumasia.com/analysis/29/27042/the-future-of-mrna-is-being-built-in-apac.html
5 months ago
0
1
0
Noxopharm has announced the first multiple-dose cohort of SOF-SKN™ has been successfully completed in the HERACLES trial. The Safety Steering Committee determined the treatment to be safe and well tolerated, with no clinically relevant issues found. More here:
www.noxopharm.com/pdf/239710c2...
loading . . .
https://www.noxopharm.com/pdf/239710c2-0c32-48a6-9e08-ee84ad920182/HERACLES-clinical-trial-Update-5.pdf?Platform=ListPage
6 months ago
0
0
0
Noxopharm has released its 2025 AGM presentation covering inflammation’s links to numerous diseases, HERACLES clinical trial progress, external interest, market opportunities and catalysts, and SOF-SKN™ advantages in a global market. Read more here:
www.noxopharm.com/pdf/f67956fe...
loading . . .
https://www.noxopharm.com/pdf/f67956fe-bc8b-40d9-8bc5-af952253ae78/Noxopharm-2025-AGM-Corporate-Presentation.pdf?Platform=ListPage
7 months ago
0
0
0
Noxopharm has announced the first dosing has been administered in the second part of the HERACLES clinical trial. This second part of the trial involves multiple doses of SOF-SKN being given to two cohorts in succession. Read more here:
www.noxopharm.com/pdf/ddeef22f...
loading . . .
https://www.noxopharm.com/pdf/ddeef22f-7682-4c42-8e58-c5c30de7c97d/First-dose-in-HERACLES-clinical-trial-Part-Two.pdf?Platform=ListPage
7 months ago
0
0
0
Noxopharm announces the awarding of a TechVoucher grant for a joint project with UNSW Sydney, who will use the funding to explore how Noxopharm’s novel anti-inflammatory oligonucleotides could be used to reduce the inflammation caused by implants. Read more here:
www.noxopharm.com/pdf/8263eb2b...
loading . . .
https://www.noxopharm.com/pdf/8263eb2b-b9ac-411f-aff4-39b3ec85a312/NSW-Government-grant-for-UNSW-collaboration.pdf?Platform=ListPage
7 months ago
0
0
0
Lupus can have severe effects on people's lives and can be hard to diagnose - read more about the disease and the latest global research in the article below.
apnews.com/article/auto...
 Disease of 1,000 faces shows how science is tackling immunity’s dark side
loading . . .
Disease of 1,000 faces shows how science is tackling immunity’s dark side
It's one of medicine's biggest mysteries — why sometimes our immune system attacks our own bodies. Autoimmune diseases affect as many as 50 million Americans and millions more worldwide.
https://apnews.com/article/autoimmune-disease-lupus-diagnosis-symptoms-b1f2ba32883c63fff1af689a45281305?utm_source=bluesky&utm_medium=share <br>Disease
7 months ago
0
0
0
Noxopharm announces the start of the HERACLES clinical trial Part II, following successful single-dose testing. Multiple doses of ascending concentrations of SOF-SKN will continue safety testing at a more intensive level over a longer period of time. More here:
www.noxopharm.com/pdf/1126c863...
loading . . .
https://www.noxopharm.com/pdf/1126c863-120b-4bd8-8069-2f613176b33e/Second-part-of-HERACLES-clinical-trial-begins.pdf?Platform=ListPage
7 months ago
0
0
0
The latest quarterly is now out, with news that Noxopharm has signed several collaboration agreements with Australian and international academic and research institutions. Read more here:
www.noxopharm.com/pdf/07c5e9d5...
loading . . .
https://www.noxopharm.com/pdf/07c5e9d5-81ae-4865-a8b1-580e37c825f8/September-2025-Quarterly-Activities-Report-and-Appendix-4C.pdf?Platform=ListPage
7 months ago
0
0
0
Great to see the Victorian Government supporting
@hudsonresearch.bsky.social
and Noxopharm's work taking our innovative SOF-SKN drug to a clinical trial and offering hope to people with lupus.
www.premier.vic.gov.au/world-first-...
loading . . .
World-First RNA Trial A Breakthrough For Lupus Patients
Melbourne researchers have developed a new RNA drug designed to prevent the damaging effects of the debilitating autoimmune disease lupus, in a major breakthrough supported by the Allan Labor Governme...
https://www.premier.vic.gov.au/world-first-rna-trial-breakthrough-lupus-patients
7 months ago
0
4
1
Noxopharm has announced it has been granted its first US patent for the Sofra™ technology platform. It relates to how Noxopharm’s innovative immune-modulatory oligonucleotides could harness the immune system for the treatment of certain cancers. Read more here:
www.noxopharm.com/pdf/96da7dc3...
loading . . .
https://www.noxopharm.com/pdf/96da7dc3-0046-4331-891d-0774825c167f/First-US-patent-for-Sofra-technology-platform.pdf?Platform=ListPage
7 months ago
0
0
0
The immune system is centre stage once again as this year's Nobel Prize in Physiology or Medicine is awarded for groundbreaking discoveries concerning peripheral immune tolerance.
www.nobelprize.org/prizes/medic...
loading . . .
Nobel Prize in Physiology or Medicine 2025
The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"
https://www.nobelprize.org/prizes/medicine/2025/popular-information/
8 months ago
0
0
0
Check out the company's latest media coverage on Stockhead. Noxopharm has the 'burning fire' of inflammation squarely in its sights:
stockhead.com.au/health/biocu...
loading . . .
Biocurious: Noxopharm has the 'burning fire' of inflammation squarely in its sights - Stockhead
After a strategy revamp Noxopharm is pursuing a clinical program targeting inflammation, notably the painful condition skin lupus.
https://stockhead.com.au/health/biocurious-noxopharm-has-the-burning-fire-of-inflammation-squarely-in-its-sights/
9 months ago
0
0
0
Noxopharm announces the fourth and last single-dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. Read more here:
www.noxopharm.com/pdf/e50f60a8...
loading . . .
https://www.noxopharm.com/pdf/e50f60a8-062f-453a-9e1c-c6244dd0952c/HERACLES-clinical-trial-Update-4.pdf?Platform=ListPage
9 months ago
0
0
0
Noxopharm has released a new Sofra™ presentation that includes an overview of the technology platform, global autoimmune disease therapeutics and cutaneous lupus market info, SOF-SKN advantages, and numerous catalysts. Read it here:
www.noxopharm.com/pdf/a11601fa...
loading . . .
https://www.noxopharm.com/pdf/a11601fa-d808-4afd-ab54-c37a9e2cbcd1/Sofra-technology-platform-presentation.pdf?Platform=ListPage
9 months ago
0
0
0
Noxopharm announces the third dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. The fourth cohort will now receive the highest dose approved for this trial. Read more here:
www.noxopharm.com/pdf/42f7ce25...
loading . . .
https://www.noxopharm.com/pdf/42f7ce25-454a-41ec-b24d-fe18c438a8b8/HERACLES-clinical-trial-Update-3.pdf?Platform=ListPage
9 months ago
0
0
0
Noxopharm is very proud to have been nominated as a finalist in this year's Health Industry Hub awards, which celebrate change-makers across the industry. Read more about all the categories and finalists here:
www.healthindustryhub.com.au/health-indus...
10 months ago
0
0
0
Noxopharm announces the second dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the third cohort of participants, who will receive a higher dose. Read more here:
www.noxopharm.com/pdf/51866b0a...
loading . . .
https://www.noxopharm.com/pdf/51866b0a-d424-43b7-9363-e11c23ccced0/HERACLES-clinical-trial-Update-2.pdf?Platform=ListPage
10 months ago
0
1
0
Noxopharm has announced initial results from US company Tezcat Biosciences testing assets from the Sofra™ technology platform. Tezcat conducted a series of preclinical in vitro studies that resulted in highly promising outcomes. Read more here:
www.noxopharm.com/pdf/6d742ee9...
loading . . .
https://www.noxopharm.com/pdf/6d742ee9-7899-40ef-86ee-7eda1c5e3284/US-company-demonstrates-strong-Sofra-potential.pdf?Platform=ListPage
10 months ago
0
0
0
Noxopharm has expanded the scope of its existing collaborations with three companies following the signing of Material Transfer Agreements several months previously. Read more news in the latest quarterly here:
www.noxopharm.com/pdf/65a545cf...
loading . . .
https://www.noxopharm.com/pdf/65a545cf-3b1f-401a-909c-40ceca7b31b5/June-2025-Quarterly-Activities-Report-and-Appendix-4C.pdf?Platform=ListPage
10 months ago
0
0
0
Noxopharm CEO Dr Gisela Mautner has featured as a panelist at Bio Connections Australia this week. The panel of accomplished female leaders discussed the role of women in the industry and how biotech companies can attract and retain more women in executive and scientific roles.
10 months ago
0
1
0
Noxopharm announces the first dose cohort of SOF-SKN™, a novel drug candidate for autoimmune diseases, has been successfully completed in the HERACLES trial. It will now proceed to the second cohort of participants, who will receive a higher dose. Read more here:
www.noxopharm.com/pdf/8dbd34b1...
loading . . .
https://www.noxopharm.com/pdf/8dbd34b1-9a29-45e0-95c7-26e3a9548100/HERACLES-clinical-trial-Update-1.pdf?Platform=ListPage
10 months ago
0
0
0
A major milestone reached with the first dose administered in the HERACLES trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. Noxopharm CEO Dr Gisela Mautner said: “We have taken our first Sofra drug candidate into the clinic at a rapid pace.”
www.noxopharm.com/pdf/e997b104...
loading . . .
https://www.noxopharm.com/pdf/e997b104-3093-4258-ad15-9f2c5a7ec005/First-SOFSKN-dose-in-HERACLES-clinical-trial.pdf
11 months ago
0
0
0
Noxopharm has announced that recruitment activities are progressing rapidly for the HERACLES clinical trial. This involves activities such as advertising, as well as the identification, pre-screening and full screening of participants. Read more here:
www.noxopharm.com/pdf/818fbb39...
loading . . .
https://www.noxopharm.com/pdf/818fbb39-e725-4d9c-a02b-8d33e507a6f3/Clinical-trial-recruitment-progressing-rapidly.pdf
11 months ago
0
0
0
Noxopharm has announced positive data generated by an overseas company that has tested novel assets from the Sofra™ platform. BioRay Pharmaceutical is a pioneer in China’s biopharmaceutical industry focusing on immune-mediated diseases. Read more here:
www.noxopharm.com/pdf/8b484f06...
loading . . .
https://www.noxopharm.com/pdf/8b484f06-b4a4-4e65-8a88-5f134be08398/Promising-Sofra-results-from-overseas-company.pdf
12 months ago
0
0
0
Noxopharm has secured Human Research Ethics Committee approval for the HERACLES first-in-human clinical trial of SOF-SKN™, a novel drug candidate for inflammatory diseases. Work now begins on site initiation, logistics, and participant recruitment. Read more here:
www.noxopharm.com/pdf/558ce5d0...
loading . . .
https://www.noxopharm.com/pdf/558ce5d0-84d9-4cc0-8439-93430d14337d/Green-light-for-HERACLES-clinical-trial.pdf
about 1 year ago
0
0
0
Noxopharm has presented clinically relevant SOF-SKN™ data at the Australian Rheumatology Association’s Annual Scientific Meeting, marking the company's first engagement at a specialist rheumatology event. Read more here:
www.noxopharm.com/pdf/31e0094f...
loading . . .
https://www.noxopharm.com/pdf/31e0094f-6ada-4fcd-afe2-da8bfee20dd2/SOFSKN-data-presented-at-rheumatology-conference.pdf
about 1 year ago
0
0
0
Noxopharm has now applied for Human Research Ethics Committee approval for the HERACLES clinical trial. CEO Dr Gisela Mautner said: “The preclinical testing phase has gone extremely well, and we have advanced our program expeditiously.” Read more here:
www.noxopharm.com/pdf/4adb03b0...
loading . . .
https://www.noxopharm.com/pdf/4adb03b0-1126-42f4-9d25-ce5cc22839de/Noxopharm-clinical-trial-submission.pdf
about 1 year ago
0
0
0
Noxopharm has signed a follow-on MTA with an international company to widen the scope of an ongoing project. CEO Dr Gisela Mautner said: “We continue to see external interest growing in our Sofra technology.” Read more in the latest quarterly here:
www.noxopharm.com/pdf/11c1c8db...
loading . . .
https://www.noxopharm.com/pdf/11c1c8db-62f1-4fd5-9906-7e3686d81763/March-2025-Quarterly-Activities-Report-and-Appendix-4C.pdf
about 1 year ago
0
0
0
Noxopharm CEO Dr Gisela Mautner said: “The accelerated pace with which we have progressed SOF-SKN reflects our determination to explore the potential of this innovative technology in a clinical setting as quickly as possible.”
about 1 year ago
0
0
0
Noxopharm’s SOF-SKN™ lupus medication has passed its final in vivo preclinical safety study ahead of regulatory submission for the upcoming HERACLES clinical trial. No clinically relevant safety issues were identified. Read more here:
www.noxopharm.com/pdf/131265aa...
loading . . .
https://www.noxopharm.com/pdf/131265aa-30c7-4ba4-af8e-7f0eb81454fe/SOFSKN-successfully-passes-final-pretrial-study.pdf
about 1 year ago
0
1
0
Noxopharm has announced an expanded program of work with Melbourne’s Hudson Institute, broadening research into critical inflammation sensors as well as their relevance to cancer. Read more here, including insight into the discovery underlying the Sofra platform:
www.noxopharm.com/pdf/c595367b...
loading . . .
https://www.noxopharm.com/pdf/c595367b-7e84-458f-8654-74b52ae9dc53/Noxopharm-expands-collaboration-with-Hudson-Institute.pdf
about 1 year ago
0
1
0
Noxopharm has engaged Doherty Clinical Trials, a highly-regarded Australian Phase 1 Unit, to deliver the upcoming HERACLES clinical trial in Melbourne. Read more here:
www.noxopharm.com/pdf/7796f57f...
loading . . .
https://www.noxopharm.com/pdf/7796f57f-682e-4b1c-ae5a-86d6ec069ea5/Doherty-Clinical-Trials-to-host-HERACLES-trial.pdf
about 1 year ago
0
1
0
Great work is being done by the volunteers at
www.dragonclaw.net
, a patient and carers-led charity supporting people suffering from autoimmune inflammatory diseases. Here’s a new video of their lupus meeting series:
drive.google.com/file/d/1k62U...
loading . . .
Home
Surviving and thriving with an autoimmune disease
https://www.dragonclaw.net
about 1 year ago
0
0
0
The Alliance for mRNA Medicines is doing great work supporting the industry, and Noxopharm is proud to be a member. Read their latest research report below, which offers real-world insights into the evolving mRNA landscape.
assets.mrnamedicines.org/uploads/2025...
over 1 year ago
0
1
0
Load more
feeds!
log in
